|
Japan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Japan Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Japan.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Japanese pharmaceutical and healthcare industry.
Competitive intelligence, Japanese pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Japanese market.
The Japan Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Japan Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Japanese pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Japan to test other views – a key input for successful budgeting and strategic business planning in the Japanese pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Japanese Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Japan.
- Exploit The Latest Competitive Japanese Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Japan.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Japan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Japan Pharmaceuticals And Healthcare Industry SWOT |
| Japan Political SWOT |
| Japan Economic SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Pharmaceuticals & Healthcare Business Environment Rankings For Q209 |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Market Summary |
| Regulatory Regime |
| Recent Regulatory Developments |
| Intellectual Property Developments |
| Pricing And Reimbursement System |
| Table: Reimbursement Categories And Rates |
| Recent Pricing and Reimbursement Developments |
| Pricing Procedures |
| Other Regulatory Issues |
| Table: Concerns Of Pharmaceutical Associations |
| International Trade Agreements |
Chapter - Industry Trends and Developments |
| Epidemiology |
| Healthcare Sector |
| Healthcare Sector Financing |
| Healthcare Reforms |
| International Reaction |
| Pharmaceutical Industry |
| Domestic Company Activity |
| Foreign Generic Sector |
| Multinational Sector Developments |
| Key developments in recent years include the following: |
| Pharmaceutical Wholesale and Retail |
| Research And Development |
| Medical Devices |
| Medical Device Regulations |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Japan – Drug Market Indicators, 2002-2013 |
| Key Growth Factors – Industry |
| Table: Japan – Healthcare Market Indicators, 2002-2013 |
| Macroeconomic Forecast Scenario |
| Longer Term Challenges Increasingly Urgent |
| Table: Japan - Macroeconomic Forecasts |
| Prescription Drug Market Forecast |
| Table: Japan – Prescription Drug Market Indicators, 2002-2013 (JPYmn unless otherwise stated) |
| OTC Medicine Market Forecast |
| Table: Japan – OTC Market Indicators, 2002-2013 (JPYmn unless otherwise stated) |
| Patented Product Market Forecast |
| Table: Japan – Patented Medicines Market Indicator, 2002-2013 (JPYmn unless otherwise stated) |
| Generic Drug Market Forecast |
| Table: Japan – Generic Drug Market Indicators, 2002-2013 (JPYmn unless otherwise stated) |
| Pharmaceutical Trade Forecast |
| Table: Japan – Pharmaceutical Export/Import Indicators, 2002-2013 (US$mn) |
| Other Healthcare Data And Forecasts |
| Table: Japan – Other Healthcare System Indicators, 2002-2013 |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Profiles |
| Leading Foreign Manufacturers |
| Pfizer |
| Sanofi-Aventis |
| Merck & Co (Banyu) |
| Novartis |
| GlaxoSmithKline (GSK) |
| AstraZeneca |
| Indigenous Manufacturers |
| Takeda |
| Astellas |
| Eisai |
| Daiichi Sankyo |
| Mitsubishi Tanabe |
| Sawai Pharmaceutical |
Chapter - Country Snapshot: Japan Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Japan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The global financial crisis has had a dramatic effect on the prospects for Japan’s US$68.9bn pharmaceutical market. In Q308 and prior to the economic downturn, we were forecasting modest growth over the next five years. However, the recession in Japan will contact both private and public spending on medicines. BMI is therefore projecting a compound annual growth rate (CAGR) of -0.33% through to 2013, when the total value of generic drug, patented products and over-the-counter (OTC) medicines will be US$67.8bn.
In February 2009, Japan's Ministry of Health, Labour and Welfare (MHLW) gave the first worldwide registration for local firm Meiji Seika's Orapenem (tebipenem pivoxil). The carbapenem is indicated for the treatment of paediatric infections resulting from resistant strains of Streptococcus pneumoniae, including persistent otitis media and pneumonia. A stand-out feature of the product is that it can be taken orally, which sick children tolerate much better than injections.
The potential of the OTC sector was put into jeopardy in February 2009. The government of Japan said it would ban the sale of drugs via the internet to ensure their legitimacy and safety. The Ministry of Health, Labour and Welfare stated that the decision would be implemented in June 2009, regardless of opposition by pharmaceutical producers.
It was revealed in February 2009 that the number of syphilis cases in Japan, including the number of congenital syphilis sufferers, has been increased since 2003, as reported by the National Institute of Infectious Diseases. This might be due to the trend for more sexual partners as well as reduced condom sales.
The potential of the OTC sector was put into jeopardy in February 2009. The government of Japan said it would ban the sale of drugs via the internet to ensure their legitimacy and safety. The Ministry of Health, Labour and Welfare stated that the decision would be implemented in June 2009, regardless of opposition by pharmaceutical producers.
|
Japan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |